Aptamer Group PLC (AIM:APTA) has entered a second Optimer development agreement with Unilever.
It follows a successful initial programme focused on inhibiting enzymes related to body odour. The new project targets a separate biological pathway.
The agreement sees Aptamer developing new binders, in return for a ‘six-figure’ fee for services.
Aptamer said the deal deepens its partnership with Unilever and expands the Optimer platform into consumer applications.
Chief executive Dr Arron Tolley highlighted that the new programme reflects Unilever’s confidence in Optimer.
“I am excited by the additional project we are undertaking with Unilever,” Tolley said.
“This project expands our partnership with Unilever in the odour control space. The excellent results produced by our team in the first project have resulted in a deepening partnership with Unilever, expanding on the applicability of our Optimer binders.”
He added: “The first project is now moving toward on-person trials, and this deal positions us well to create multiple, licensable assets with a global powerhouse in the consumer health …